Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
C. Kraynack, M.D. was appointed to Cleveland Clinic Children’s in 2013 to the Department
of Pediatrics ND Center for Pediatric Pulmonary Medicine. He is the Medical
Director of the Pediatric Solid Organ Transplant and Pediatric Lung Transplant
has been board-certified in pediatrics and pediatric pulmonary medicine. He
cares for children and young adults with all forms of pediatric lung conditions
such as asthma, bronchopulmonary dysplasia, chronic lung disease of
prematurity, chronic respiratory failure, and those children requiring
technological assistance to breathe effectively. In particular, he has a keen
interest in children with Cystic Fibrosis, other forms of bronchiectasis, end
stage lung disease and those requiring or having had a lung transplant.
as the head of a large accredited Cystic Fibrosis Center for almost ten years,
he has a wealth of experience in caring for these patients with their complex
medical needs. He and his team realized that inconsistent care for this
condition across Cystic Fibrosis Care Center was prevalent and may be
contributing to variable outcomes1. Heading a multidisciplinary team
of caregivers, his team developed standardized protocols for cystic fibrosis
care that had not previously been used and were associated with dramatic
improvement in patient outcomes at their center2. These protocols
have since been adopted at other care centers nationally and internationally on
at least three continents. His passion for standardized care has extended to
nutritional protocols for patients with cystic fibrosis, non-cystic fibrosis
bronchiectasis, inpatient management for patients with cystic fibrosis, asthma,
and those patients with chronic respiratory failure and lung transplantation.
Dr. Kraynack has been
named one of the Best Doctors in America since 2009. He has been a principal
investigator of translational research trials and a number of multicenter
clinical trials for patients with Cystic Fibrosis. He is the Pediatric Representative for the
Transplant Center Advisory Council at Cleveland Clinic. As an Associate
Professor of Pediatrics at the Cleveland Clinic Lerner College of Medicine and
Case Western University and the Northeast Ohio Medical University (Rootstown,
OH), he is active in medical education of medical students and pediatric
An invited lecturer at
national and international medical meetings, Dr. Kraynack is a recognized
expert in the field of Cystic Fibrosis and the implementation of Quality
Improvement programs to improve patient outcomes.
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 6/7/2017, Dr. Kraynack has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.